Home/ Stocks/ PASG

Passage Bio, Inc. Common Stock

PASG XNAS

$4.21 +0.21 (+5.15%) ▲ 15-min delayed

Open

$4.13

High

$4.26

Low

$3.94

Volume

112.5K

Market Cap

$13.50M

About Passage Bio, Inc. Common Stock

Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 24 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	N/A	$-45,522,000	$-14.35
FY 2025	N/A	$-45,522,000	$-14.35
Q3 2025	N/A	$-7,749,000	$-2.44
Q2 2025	N/A	$-9,385,000	$-2.96

Related Market News

No specific coverage for PASG yet. Check out our latest market news or earnings calendar.

Get PASG Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Passage Bio, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.